AIVIS, a leading provider of AI-powered digital pathology solutions, has announced a strategic partnership with NAVER Cloud to accelerate the deployment and adoption of its flagship software platform, Qanti® IHC, across Korea’s healthcare ecosystem. Through this collaboration, AIVIS’s suite of AI pathology analysis solutions will be available on the NAVER Cloud Platform Marketplace, enabling hospitals, research institutes, and pharmaceutical companies to access AIVIS’s tools within NAVER Cloud’s secure, high-performance infrastructure. Qanti® IHC, AIVIS’s core offering, is a medical software solution that uses AI to analyze digitally scanned immunohistochemistry (IHC) tissue images with high precision. It delivers objective, cell-level quantification of key biomarkers—reducing interpretive variability and enhancing reproducibility in both clinical and research settings. AIVIS’s complementary tool, Qanti Micro, extends accessibility by enabling rapid analysis of Ki-67 from microscope-captured images, eliminating the need for costly whole-slide scanners. As part of the agreement, AIVIS will provide comprehensive support to NAVER Cloud users, including technical documentation, installation guidance, real-time troubleshooting, and regular software updates. “Partnering with NAVER Cloud represents a major step forward for our cloud-based expansion strategy,” said Daehong Lee, CEO of AIVIS. “It combines our next-generation AI capabilities with a trusted digital infrastructure to make advanced pathology tools more accessible and secure for clinical teams across Korea.” NAVER Cloud, which holds top certifications in data privacy and information security, offers an ideal platform for organizations managing sensitive medical data. The partnership also positions AIVIS to scale its SaaS (Software as a Service) model more broadly across the medical and research sectors. A NAVER Cloud spokesperson added, “We are pleased to support AIVIS in delivering cutting-edge pathology AI to more users. This collaboration aligns with our broader commitment to strengthening Korea’s medical AI ecosystem through partnerships with high-potential technology innovators.” Founded in 2021, AIVIS specializes in AI-driven biomarker quantification for cancer diagnostics. Its proprietary software, Qanti®, is approved by Korea’s Ministry of Food and Drug Safety (MFDS) and certified under GMP and ISO 13485 standards. The company develops clinically relevant tools through close collaboration with its team of board-certified pathologists. AIVIS’s solutions are currently deployed at major hospitals across Korea and are backed by global partnerships with Philips and AstraZeneca.